Scientists suggest understanding ecDNA’s role in pancreatic cancer could potentially guide future strategies for making ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

Patients with pancreatic cancer who participate in clinical research have better outcomes. PanCAN strongly recommends clinical trials at diagnosis and during every treatment decision. Clinical trials ...

The biotech company Dynamic42, a specialist in organ-on-chip technology, has made a significant advance in pancreatic cancer ...

The microbiome shapes development of insulin-producing cells in infancy, leading to long-term changes in metabolism and diabetes risk, new research in mice has found.

Professor Teusch and Dynamic42 set out their work in one of the most challenging cancers, with PDAC being the most common and lethal form of pancreatic cancer. A major cause of it ...

Portuguese researchers identified a type of immune cell that appears to travel to the pancreas to stimulate glucagon ...

Advances in stem cell biology and immune cell engineering bring diabetes cell therapies closer to reality. I n 2024, a woman ...

Some colorectal and pancreatic cancers may be resistant to KRAS G12C inhibitors due to co-occurring genetic alterations, according to a study published in the AACR journal Clinical Cancer Research.

The group recently published a case-control study showing high sensitivity and specificity, with little drop in early-stage disease, compared to late-stage cancer.

CPRIT-funded program advances work of Daniel Romo, Ph.D., to develop a new therapeutic for pancreatic cancer ...